Cisplatin Disrupts the Latency of Human Herpesvirus 8 and Induces Apoptosis in Primary Effusion Lymphoma Cells

REFERENCES

• Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865–1869.
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276–1280.
   PubMed Web of Science ®Google Scholar
• Boshoff C, Chang Y. Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu Rev Med 2001;52:453–470.
   Google Scholar
• Chandran B. Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. J Virol 2010;84:2188–2199.
   PubMed Web of Science ®Google Scholar
• Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010;289:140–150.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008;140:13–24.
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372–4380.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003;10:1663–1682.
   PubMed Web of Science ®Google Scholar
• Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 2008;13:11–32.
   PubMed Web of Science ®Google Scholar
• Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899–2908.
   PubMed Web of Science ®Google Scholar
• Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010;396:85–89.
   PubMed Web of Science ®Google Scholar
• Friborg J, Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889–894.
   PubMed Web of Science ®Google Scholar
• Katano H, Sato Y, Sata T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 2001;92:3076–3084.
   PubMed Web of Science ®Google Scholar
• Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793–805.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030–9040.
   PubMed Web of Science ®Google Scholar
• Katano H, Hoshino Y, Morishita Y, Nakamura T, Satoh H, Iwamoto A, Herndier B, Mori S. Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol 1999;58:394–401.
   PubMed Web of Science ®Google Scholar
• Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996;2:342–346.
   PubMed Web of Science ®Google Scholar
• Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 1996;88:2648–2654.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cilia AM, Gloghini A, Capello D, Todesco M, Quattrone S, Volpe R, Gaidano G. Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol 1998;102:1081–1089.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Capello D, Cilia AM, Gloghini A, Perin T, Quattrone S, Migliazza A, Lo Coco F, Saglio G, Ascoli V, Carbone A. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Genes Chromosomes Cancer 1999;24:16–23.
   PubMed Web of Science ®Google Scholar
• Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, Warnke RA, Strauchen JA, Matutes E, Kamel OW, Moore PS, Weiss RA, Chang Y. Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 1998;91:1671–1679.
   PubMed Web of Science ®Google Scholar
• Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol 2007;81:1912–1922.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM. Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413–5417.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Tolis C, Kalogera-Fountzila A, Karanikiotis C, Bai M, Misailidou D, Samantas E, Athanassiou E, Papamichael D, Tsekeris P, Catodritis N, Nicolaou A, Plataniotis G, Makatsoris T, Papakostas P, Zamboglou N, Daniilidis J. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma: a hellenic cooperative oncology group phase II study. Strahlenther Onkol 2005;181:223–230.
   PubMed Web of Science ®Google Scholar
• Weinrib L, Li JH, Donovan J, Huang D, Liu FF. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Cancer Gene Ther 2001;8:352–360.
   PubMed Web of Science ®Google Scholar
• Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662–1670.
   PubMed Web of Science ®Google Scholar
• Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007;117:1019–1028.
   PubMed Web of Science ®Google Scholar
• Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005;115:642–652.
   PubMed Web of Science ®Google Scholar
• Hussain AR, Khan AS, Ahmed SO, Ahmed M, Platanias LC, Al-Kuraya KS, Uddin S. Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Prolif 2010;43:170–183.
   PubMed Web of Science ®Google Scholar
• Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999;190:1025–1032.
   PubMed Web of Science ®Google Scholar